<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02149160</url>
  </required_header>
  <id_info>
    <org_study_id>FRM-0334-002</org_study_id>
    <secondary_id>2014-001489-85</secondary_id>
    <nct_id>NCT02149160</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FORUM Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FORUM Pharmaceuticals Inc</source>
  <brief_summary>
    <textblock>
      The purposes of this study are to investigate the safety, tolerability, and pharmacodynamics
      of FRM-0334 in subjects with prodromal to moderate frontotemporal dementia with granulin
      mutation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the safety and tolerability of FRM-0334</measure>
    <time_frame>Baseline to Day 28 or Early Termination</time_frame>
    <description>Number and percentage of subjects with AEs
Number and percentage of subjects with SAEs
Number and percentage of subjects who discontinue due to AEs
Number and percentage of subject deaths</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the pharmacodynamic (PD) effects of FRM-0334 on the change from baseline in plasma concentrations of progranulin (PGRN) after 28 days</measure>
    <time_frame>Baseline to Day 28 or Early Termination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the pharmacodynamic effects of FRM-0334 on the change from baseline in cerebrospinal fluid (CSF) concentrations of PGRN after 28 days</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Change in CSF progranulin concentration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the plasma concentrations of FRM-0334 and metabolites following once daily dosing for 28 days</measure>
    <time_frame>Day 1 to Day 28 or Early Termination</time_frame>
    <description>Cmax, Ctrough, tmax, t1/2, λz, AUC(0-τ), CL/F, Cav in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the CSF concentrations of FRM-0334 and metabolites following once daily dosing for 28 days</measure>
    <time_frame>Day 1 to Day 28 or Early Termination</time_frame>
    <description>Cmax, Ctrough, tmax, t1/2, AUC0-τ, CL/F, Cav in CSF</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Granulin Mutation</condition>
  <arm_group>
    <arm_group_label>FRM-0334; Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose, Capsule, Once Daily, Day 1 through Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FRM-0334; Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose, Capsule, Once Daily, Day 1 through Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator; Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, Capsule, Once Daily, Day 1 through Day 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FRM-0334</intervention_name>
    <arm_group_label>FRM-0334; Arm 1</arm_group_label>
    <arm_group_label>FRM-0334; Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Comparator; Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ages aged ≥21 and ≤75 years

          -  Genotyped positive for a FTD-GRN mutation, and aware of it

          -  Prodromal to moderate FTD-GRN

          -  Resides in a stable living situation, living at home, senior residential setting, or
             an institutional setting without the need for continuous (ie, 24-hour) nursing care

          -  Proficiency (oral and written) in the language in which study-related documents,
             including the ICF and standardized tests, will be administered

          -  Able to swallow capsules

          -  Be in good general health, willing and able to comply with the protocol requirements,
             and expected to complete the study as designed (in the judgment of the investigator)

        Exclusion Criteria:

          -  Clinically significant abnormalities on physical examination, medical history, ECG,
             vital signs, laboratory values, or unstable medical or psychiatric illness

          -  Females who are pregnant, breastfeeding, or planning to become pregnant during the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSF Memory and Aging Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perelman School of Medicine, University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux Hospital Pellegrin</name>
      <address>
        <city>Bordeaux Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rouen, Charles Nicolle Hospital</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS - Centro S. Giovanni di Dio FateBeneFratelli</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Clinic, University of Brescia, AO Civil Hospital of Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Universita Gabriele D'Annunzio di Chieti</name>
      <address>
        <city>Chieti Scalo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The National Hospital for Neurology and Neuroscience</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>May 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Histone deacetylase inhibitor</keyword>
  <keyword>Frontotemporal dementia</keyword>
  <keyword>Granulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

